Olverembatinib (HQP-1351)
Revision as of 11:19, 16 August 2023 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Third-generation TKI ==Diseases for which it is used== *Chronic myeloid leukemia ==History of changes in NMPA indication== *2021-11: Initial cond...")
Mechanism of action
Third-generation TKI
Diseases for which it is used
History of changes in NMPA indication
- 2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant CML-CP or CML-AP harboring the T315I mutation as confirmed by a validated diagnostic test. (Based on HQP1351CC203)
Also known as
- Code name: HQP-1351